ADIPOQ and obesity disorder: Surendar et al. [8] demonstrated for the first time that in a background of obesity, adiponectin reduces the production of IFN-γ and IL-17 by inhibiting glycolysis in Th1 and Th17 cells, thus alleviating the development of inflammation.